PubMed Health⌕ Search

PubMed · 1006202

[Residual dimension and defect].

Abstract

We approached the current problem of the residual dimension of psychoses, a problem of significance from both the psychopathological and social-psychiatric viewpoint by studying two well-matched groups of patients suffering from cycloid (schizo-affective) psychosis and hebephrenia. On the basis of the short-term course of the psychosis, we reached the following conclusions: 1. The residual dimension is not uniform, not homogenous and is not nosologically neutral, but is complex, multifold and nosospecific to a significant extent. 2. Assessment of the residual syndrome on "vorgestalt" level is indispensable for analysis of the residual dimension in cycloid psychotics and is also value in the case of heberphrenics (within the group of systematic schizophrenics). 3. We speak of a clinical defect in the case of a stable link between manifest symptoms which point more towards a disorder in the life functions and symptoms of resocialization more related to the life history; detectable defect is used in referring to a stable link between symptoms which are detectable (by test psychology methods) and disorders in resocialization. It must be stressed that the assessment of the psychiatric defect is a doubly resignated way of knowledge as compared to defects which can be evaluated on the anthropological level; however the empirical value derives precisely from the consciously accepted limitation. 4. We found clinical defects only in the heberphrenics. A cognitive defect was detected in the cycloids and a personally defect in the heberphrenics.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B Pethö, K H Szabó, K Mórotz, B Hajtman, L S Sajgó-Molnár. 1976. [Residual dimension and defect].. https://pubmed.ncbi.nlm.nih.gov/1006202/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Developing psychological perspectives of suicidal behaviour and risk in people with a diagnosis of schizophrenia: we know they kill themselves but do we understand why?

People with a diagnosis of schizophrenia are at increased risk of suicidal behaviour yet little is understood of the psychological underpinnings of this vulnerability. The biopsychosocial 'Cry of Pain' model [Williams, J.M.G. (1997). Cry of pain. Harmondsworth: Penguin.] provides a broad framework from which to understand suicidal behaviour. However, the utility of the model in relation to suicide in schizophrenia has not yet been explored. This was the primary goal of this paper. Six components of the 'Cry of Pain' model were identified and evaluated with respect to whether they contributed to i. common transdiagnostic factors underlying suicide, ii. factors relating to co-morbid depression which account for suicidal behaviour, or iii. factors which are specific to schizophrenia and underlie suicide risk. The potential for applying the model to clinical management of suicide in schizophrenia is illustrated.

Cognition Disorders↗

Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB.

OBJECTIVE: Over the last decade, the Cambridge Neuropsychological Test Automated Battery (CANTAB), which comprises visuo-spatial tasks, has been utilized in cognitive studies of schizophrenia. A clear approach concerning the usage of CANTAB for the appraisal of neurocognitive dysfunction in schizophrenia is currently lacking. METHOD: In this paper, we have first reviewed the overall applications of CANTAB and then evaluated methodological strengths and weaknesses of CANTAB as a neurocognitive battery for schizophrenia. We carried out a systematic search and assessment of studies where CANTAB was utilized to measure cognitive function in schizophrenia. We have also attempted to quantify the available data and perform a meta-analysis, but this approach turned out to be still premature. RESULTS: CANTAB has enabled researchers to highlight significant deficits affecting broad cognitive domains in schizophrenia, such as working memory, decision-making, attention, executive functions and visual memory. So far, the most consistent deficit observed with CANTAB testing has been attentional set-shifting, suggestive of fronto-striatal dysfunctions. In addition, preliminary evidence points towards the potential use of CANTAB to identify cognitive predictors of psychosocial functioning, to describe the relationships between symptoms and cognition, and to measure the impact of pharmacological agents on cognitive functioning. CONCLUSION: CANTAB has been used successfully to highlight the range of visuo-spatial cognitive deficits in schizophrenia, producing similar results to those obtained with some traditional neuropsychological tests. Further studies validating the use of CANTAB following the standard set by Measurement And Treatment Research to Improve Cognition in Schizophrenia (MATRICS) are warranted.

Cognition Disorders↗